Overall Abstract: Schizophrenia is associated with a reduced life expectancy of 15-20 years due to a high prevalence of cardiovascular disease and metabolic syndrome. Unhealthy lifestyles and pharmacological side effects have been suggested to be a major cause of excess mortality rates in patients with psychotic disorders. However, abnormal glucose homeostasis, hyperinsulinemia and accumulation of visceral fat are already detected in drug-naïve first episode psychosis (FEP) patients, independently of obesity. The aim of this symposium is to present the latest research on the theme of metabolic co-morbidities in psychotic disorders. Preliminary and published data from the symposium speakers suggests that FEP is associated with altered composition of gut microbiota, inflammation and lipid dysregulation including changes in the endocannabinoid system in the central nervous system. The studies presented in this symposium may offer new insights into the gut-brain axis in psychotic disorders as well as provide new evidence on the role of lipids as a potential underlying link between the aetiology of psychosis and the associated metabolic disturbances. All four speakers are principal investigators in the European FP7 project METSY, which aims to identify and evaluate multi-modal peripheral and neuroimaging markers that can predict and monitor psychotic and metabolic symptoms, with specific focus on metabolic co-morbidities in psychotic disorders. Oliver Howes will first introduce the topic, based on his recent meta-analysis (JAMA Psychiatry 2017; 74; 261-269) as well as present his recent research on neuroimaging of the endocannabinoid system in FEP. Jaana Suvisaari will present her recent research on gut microbiome and inflammation in FEP. The findings so far suggest that FEP patients have specifically altered gut microbiome composition and increased levels of inflammation. Tuulia Hyötyläinen will introduce the field of metabolomics in psychosis research and discuss the latest findings from at-risk mental state individuals and FEP patients. Recently published findings suggest that FEP patients who later rapidly gain weight are characterised by increased markers of liver fat at the baseline. Jarmo Hietala will present neuroimaging studies of the endocannabinoid system using PET and the [18F]FMPEP-d2 tracer, a CB1R radioligand. These studies suggest a major sex difference in the brain CB1 receptor system as well as clear evidence for a dysregulated endocannabinoid system in first-episode psychosis. Given the endocannabinoid system in the periphery promotes the development of fatty liver, the presented work together suggests that the endocannabinoid system may be the underlying link between the psychosis and the associated metabolic disturbances. This intriguing possibility with potential diagnostic and therapeutic implications will be discussed by the presenters. Background: People with schizophrenia die on average 15-20 years earlier than the general population, and the mortality gap has grown in recent years. Non-CNS, particularly cardio-metabolic, causes account for the majority of this premature mortality. Abnormalities in the cardio-metabolic and immune system are well established in patients with schizophrenia, but it is unknown if abnormalities are present in people at risk of psychosis and at illness onset prior to antipsychotic treatment, and how they compare to neurofunctional measures. To address this, we conducted a series of metaanalyses and meta-regressions to determine the magnitude and consistency of findings and influence of antipsychotic treatment, exercise and other factors across cardio-metabolic parameters at onset of psychosis. Methods: We conducted a meta-analysis of peripheral gluco-regulatory, immune and lipid measures and comparison with brain neurofunctional outcomes (including N-acetyl aspartate, gray matter volume and auditory P300 measures) in studies of clinical high risk samples and first episode psychosis, focusing on drug naïve patients. The entire PubMed, EMBase and PsychInfo databases were searched to identify relevant studies. Then we conducted a meta-review statistical comparison of cardio-metabolic and immune function with neurofunctional measures. Results: 35 studies (>1500 patients and controls) were included in the metaanalyses. Interleukin-6 (g=2.2, p=0.013), and TNF-alpha (g=0.94, p<0.01) levels and fasting insulin and post-challenge glucose levels were elevated with moderate-large effect sizes (g=0.4, p=0.01; g=0.6, p=0.007 respectively) and cholesterol and low density lipoprotein levels were reduced (g=-0.2, p=0.005, and g=-0.22, p=0.001 respectively), whilst triglyceride levels were increased (g=0.14, p<0.05). These findings remained significant in drug naïve patients and after adjusting for the influence of a number of potential confounders (including body mass, exercise levels, smoking). N-acetyl aspartate levels in frontal cortex and auditory P300 amplitude (g=0.83, p<0.0001) were significantly altered in first episode patients relative to controls. The median effect sizes for cardiometabolic dysfunction (g=0.41) was comparable to that of the neurofunctional measures (g=0.42, p>0.3). Moreover, the median effect size for immune alterations (g=1.3) was significantly greater than that for neurofunctional measures (p=0.002). Discussion: We demonstrate that effect sizes for markers of cardio-metabolic and immune disturbance are comparable in magnitude to those for markers of neurofunctional CNS disturbances from the onset of psychosis, suggesting schizophrenia involves multiple organ systems from illness onset. The three main pathoetiological models by which CNS and non-CNS abnormalities may co-occur in schizophrenia will be discussed. The shared genetic and environmental risk architecture between schizophrenia and cardiometabolic disorders suggests common aspects of pathoetiology.
BODY AND MIND: CARDIO-METABOLIC AND IMMUNE FUNCTION IN FIRST EPISODE PSYCHOSIS AND COMPARISON WITH CENTRAL NEUROFUNCTIONAL MEASURES
Oliver Howes* Background: People with schizophrenia die on average 15-20 years earlier than the general population, and the mortality gap has grown in recent years. Non-CNS, particularly cardio-metabolic, causes account for the majority of this premature mortality. Abnormalities in the cardio-metabolic and immune system are well established in patients with schizophrenia, but it is unknown if abnormalities are present in people at risk of psychosis and at illness onset prior to antipsychotic treatment, and how they compare to neurofunctional measures. To address this, we conducted a series of metaanalyses and meta-regressions to determine the magnitude and consistency of findings and influence of antipsychotic treatment, exercise and other factors across cardio-metabolic parameters at onset of psychosis. Methods: We conducted a meta-analysis of peripheral gluco-regulatory, immune and lipid measures and comparison with brain neurofunctional outcomes (including N-acetyl aspartate, gray matter volume and auditory P300 measures) in studies of clinical high risk samples and first episode psychosis, focusing on drug naïve patients. The entire PubMed, EMBase and PsychInfo databases were searched to identify relevant studies. Then we conducted a meta-review statistical comparison of cardio-metabolic and immune function with neurofunctional measures. Results: 35 studies (>1500 patients and controls) were included in the metaanalyses. Interleukin-6 (g=2.2, p=0.013), and TNF-alpha (g=0.94, p<0.01) levels and fasting insulin and post-challenge glucose levels were elevated with moderate-large effect sizes (g=0.4, p=0.01; g=0.6, p=0.007 respectively) and cholesterol and low density lipoprotein levels were reduced (g=-0.2, p=0.005, and g=-0.22, p=0.001 respectively), whilst triglyceride levels were increased (g=0.14, p<0.05). These findings remained significant in drug naïve patients and after adjusting for the influence of a number of potential confounders (including body mass, exercise levels, smoking). N-acetyl aspartate levels in frontal cortex and auditory P300 amplitude (g=0.83, p<0.0001) were significantly altered in first episode patients relative to controls. The median effect sizes for cardiometabolic dysfunction (g=0.41) was comparable to that of the neurofunctional measures (g=0.42, p>0.3). Moreover, the median effect size for immune alterations (g=1.3) was significantly greater than that for neurofunctional measures (p=0.002). Discussion: We demonstrate that effect sizes for markers of cardio-metabolic and immune disturbance are comparable in magnitude to those for markers of neurofunctional CNS disturbances from the onset of psychosis, suggesting schizophrenia involves multiple organ systems from illness onset. The three main pathoetiological models by which CNS and non-CNS abnormalities may co-occur in schizophrenia will be discussed. The shared genetic and environmental risk architecture between schizophrenia and cardiometabolic disorders suggests common aspects of pathoetiology. Background: Patients with first-onset psychosis have evidence of impaired glucose tolerance, but otherwise are metabolically healthy when traditional cardiovascular risk markers are used. After antipsychotic treatment is started, there is rapid weight gain and emergence of dyslipidemias. Weight gain and development of abdominal obesity is accompanied by worsening chronic low-grade inflammation. Activation of innate immunity is often present at the onset of disease. One unexplored mechanism possibly contributing to these problems is altered gut microbiota. Methods: The Helsinki Early Psychosis Study recruited 97 patients with first-episode psychosis and 62 controls into a longitudinal study. Here, data on longitudinal changes in inflammation, weight gain and abdominal obesity during the first year of treatment in patients with first-episode psychosis is presented and compared with matched healthy controls. Three time points (baseline, 2 months, 12 months) are available for patients and two (baseline, 12 month) for controls. The possible contribution of different antipsychotics will be explored, and whether patients who were no longer using antipsychotics at the one-year follow-up have less problems in these measures. First results regarding the gut microbiome will be presented (Schwarz et al. 2017) , and the possible contribution of gut microbiota to inflammation and weight gain in first-episode psychosis explored. Results: Our previous findings from a subset of the study sample found most marked changes in innate immunity chemokines (Mäntylä et al. 2015) , whereas full longitudinal data on 38 cyto-and chemokines will be available at the SIRS congress. As a preliminary result on the longitudinal course of inflammation, high-sensitivity C-reactive protein showed a significant increase during the first year of treatment in patients (median baseline 0.65 mg/l, 2 months 0.79 mg/l and 12 months 1.68 mg/l). Data on PBMC gene expression will also be presented, revealing notable differences related to different antipsychotic use. Background: Psychotic patients are at high risk for developing obesity, metabolic syndrome and type 2 diabetes. These metabolic co-morbidities are hypothesized to be related to both treatment side-effects as well as to metabolic changes occurring during the psychosis. Earlier metabolomics studies have shown that blood metabolite levels are predictive of insulin resistance and type 2 diabetes in the general population as well as sensitive to the effects of antipsychotics. Here we aimed to identify the metabolite profiles predicting future weight gain and other metabolic abnormalities in psychotic patients. Methods: We applied metabolomics to investigate serum metabolite profiles in a prospective study setting in 36 first-episode psychosis patients during the first year of the antipsychotic treatment and 19 controls. Two analytical platforms with broad analytical coverage were used. Molecular lipids were analysed by ultra-high performance liquid chromatography coupled to time-of-flight mass spectrometry (UHPLC_QTOFMS) and polar metabolites were analysed by two-dimensional gas chromatography coupled to TOFMS (GCxGC-TOFMS). Ongoing prospective metabolomics studies ae focusing on the subjects in at-risk mental state. Results: While corroborating several earlier findings when comparing cases and controls and the effects of the antipsychotic medication, we also found that prospective weight gain in psychotic patients was associated with increased levels of triacylglycerols with low carbon number and double-bond count at baseline and independent of obesity, that is, lipids known to be associated with increased liver fat. Discussion: The first-episode psychotic patients who rapidly gain weight in the follow-up have early metabolic disturbances which are associated with insulin resistance and fatty liver. Our studies suggest that metabolite profiles may be used to identify the psychotic patients most vulnerable to develop metabolic co-morbidities, and may point to a pharmacological approach to counteract the antipsychotic-induced weight gain.
INFLAMMATION AND GUT MICROBIOME IN FIRST-EPISODE PSYCHOSIS

THE ENDOCANNABINOID SYSTEM IN FIRST-EPISODE PSYCHOSIS
Jarmo Hietala* ,1
University of Turku
Background: The endocannabinoid (EC) system comprises of fatty acid neurotransmitters such as anandamide and 2-acylglycerol, at least two specific cannabinoid (CB) receptor subtypes and enzyme machinery for synthesis and degradation of ECs. The EC system regulates a wide array of functions in central nervous system and peripheral tissues such as brain development, plasticity, reward and stress sensitivity as well as metabolic functions a such as energy/lipid metabolism including liver function and insulin resistance (1). One of the aims of the METSY project (www.metsy.eu) is to study the central and peripheral EC system in FEPs and their involvement in brain mechanisms in psychosis as well as related metabolic co-morbidities. The cannabinoid CB1 receptor (CB1R) is the most abundant cannabinoid receptor subtype in the human brain and is the predominant mediator of various EC effects. In this first series of METSY experiments we report in vivo brain CB1R binding characteristics in patients with first-episode psychosis (FEP) and controls. Methods: Brain CB1R availability was measured using [18F]-FMPEP-d2 and 3D ECAT HRRT positron emission tomography (PET) using distribution volume (DVt) as a proxy for CB1R availability. Our studies in healthy volunteers revealed a marked sex difference in [18F]-FMPEP DVt with males having higher CB1R availability. The overall CB1R sex difference was widespread but also regionally different with most significant effects in the occipital cortex. Therefore, subsequent studies focused first on male patients with FEP and controls (n=18).
Results:
The results indicate a significant and relatively widespread decrease in CB1R DVt in patients with FEP in fronto-temporal regions, putamen, posterior cingulate as well as parietal regions with large effect sizes. Largely similar results were seen in an independent sample of medication-free male patients with FEP (n=17, the other METSY PET site, King's College, London, UK) (2). Those studies used another validated CB1R tracer, the [11C]-MePPEP. The reduced CB1R in patients was also state-dependent as [18F]-FMPEP DVt correlated negatively with psychotic symptoms (BPRS) in a highly significant manner. Discussion: Epidemiological studies have convincingly shown that cannabis use is associated with an increased risk of both psychotic symptoms and schizophrenia-like psychoses. We now provide direct in vivo evidence for a robust and partly state-dependent dysregulation of the endocannabinoid system in first-episode psychosis. This is well in line with a recent PET study with CB1R tracer, [11C]-OMAR in patients with schizophrenia (3). Based on previous experimental data the reduced CB1R availability is indicative of an increased endocannabinoid drive in psychosis. Acknowledgements: Funding from the EU's 7th Framework Programme; METSY -Neuroimaging platform for characterization of metabolic comorbidities in psychotic disorders (no. 602478). 
